LDLR and homozygous familial hypercholesterolemia: A recent study by Wiegman et al. [34] presented evinacumab, a novel LDLR-independent lipid-lowering therapy, which has proven effective in reducing LDL-C levels by nearly 50% in high-risk pediatric HoFH patients, demonstrating both its efficacy and safety.